Vanersborg

Researchers are evaluating the risk of developing pancreatic cancer in adults with type 2 diabetes mellitus (T2DM) who started treatment with exenatide compared to those who began treatment with other glucose-lowering drugs that are not glucagon-like peptide 1 receptor agonists (GLP-1 RA). This non-interventional post-authorization safety study, called EXCEED, will collect data retrospectively from medical and prescription records across seven European countries between 2006 and 2023. Patients included are aged 18 years or older and have a diagnosis of T2DM. The study groups include patients who initiated exenatide treatment and those who started other non-GLP-1 RA based glucose-lowering drugs (GLDs) without prior use of exenatide. Initiators of exenatide will be identified by specific drug codes and included regardless of previous use of other GLDs. The comparator group consists of patients who have not used exenatide or certain other related drugs before or during the study period. Treatment exposure is determined from prescription or insurance claim records. Matching based on patient characteristics and timing will be done to compare groups accurately. Participants' medical histories, prescriptions, and diagnoses will be reviewed for at least 12 months before starting the study drug. The main outcomes measured are the rate of new pancreatic cancer diagnoses and the relative risk of developing pancreatic cancer during an average follow-up of 1.5 years or less. Data from multiple European databases will be analyzed using an intention-to-treat approach to assess safety. Patients with prior cancers (except nonmelanoma skin cancer) or pancreatic diseases will be excluded to ensure accurate results.

Researchers are evaluating two types of digital training programs supervised by physiotherapists compared to daily physical activity in adults aged 18 to 50 with low back pain lasting more than three months. The study aims to understand clinical outcomes, imaging changes in the spine using MRI, and patient-reported measures to identify exercise-related differences over time. Participants will be randomly assigned to one of three groups: supervised digital training focusing on core stability, supervised digital training focusing on aerobic exercise, or non-supervised daily physical activity with training instructions. The interventions are delivered digitally and guided by experienced physiotherapists for the supervised groups, while the third group follows daily physical activity recommendations without supervision. Throughout the study, participants will undergo clinical examinations, MRI scans, and complete patient-reported outcome questionnaires at the start and during follow-ups. Researchers will measure changes in pain levels and spine tissue characteristics over six and twelve months. The study includes careful monitoring and evaluation to assess the impact of the different training approaches on low back pain.